CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more
CrystalGenomics Inc (083790) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.129x
Based on the latest financial reports, CrystalGenomics Inc (083790) has a cash flow conversion efficiency ratio of -0.129x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-11.39 Billion) by net assets (₩87.96 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CrystalGenomics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how CrystalGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CrystalGenomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CrystalGenomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Plastron Precision Co Ltd
TWO:6185
|
0.049x |
|
Marmaris Altinyunus Turistik Tesisleri AS
IS:MAALT
|
0.078x |
|
Leo Lithium Limited
PINK:LLLAF
|
-0.017x |
|
NL Industries Inc
NYSE:NL
|
0.020x |
|
Zhejiang Taimei Medical Technology Co., Ltd.
F:A2V
|
-0.017x |
|
Ramayana Lestari Sentosa Tbk
JK:RALS
|
0.001x |
|
Prairie Operating Co.
F:7C5
|
N/A |
|
EURO PRATIK SALES LIMITED
NSE:EUROPRATIK
|
N/A |
Annual Cash Flow Conversion Efficiency for CrystalGenomics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of CrystalGenomics Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩98.52 Billion | ₩-25.85 Billion | -0.262x | -17.63% |
| 2023-12-31 | ₩145.29 Billion | ₩-32.41 Billion | -0.223x | -72.08% |
| 2022-12-31 | ₩188.28 Billion | ₩-24.40 Billion | -0.130x | -135.12% |
| 2021-12-31 | ₩207.84 Billion | ₩-11.46 Billion | -0.055x | +27.74% |
| 2020-12-31 | ₩214.76 Billion | ₩-16.38 Billion | -0.076x | -59.32% |
| 2019-12-31 | ₩149.05 Billion | ₩-7.14 Billion | -0.048x | -632.04% |
| 2018-12-31 | ₩184.47 Billion | ₩-1.21 Billion | -0.007x | -136.69% |
| 2017-12-31 | ₩91.59 Billion | ₩1.63 Billion | 0.018x | +117.86% |
| 2016-12-31 | ₩83.16 Billion | ₩-8.30 Billion | -0.100x | -51.96% |
| 2015-12-31 | ₩71.94 Billion | ₩-4.73 Billion | -0.066x | +3.72% |
| 2014-12-31 | ₩55.03 Billion | ₩-3.75 Billion | -0.068x | -- |